Bajaj Healthcare gains 11 percent after receiving DRDO nod to manufacture 2-DG
Published On: Thursday, July 8, 2021 | By: Team KnowMyStock
Shares of Bajaj Healthcare surged 11 per cent and hit 52 weeks high of Rs 1,009.80 on the BSE in intra-day trade on Thursday after the company received a licence from Defence Research and Development Organisation (DRDO) to manufacture and market "2-Deoxy-D-Glucose" (2-DG) as approved medication for the treatment of COVID-19 patients. The 2-DG Ccovid-19 control and treatment drug has been developed by the DRDO laboratory's Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with the pharma major Dr Reddy’s Laboratories. It has already received emergency approval from the Drugs Controller General of India (DCGI) for use on Covid-19 patients in the country. The drug comes in powder form and retails at Rs 990 per sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.
Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add 2-Deoxy-D-Glucose to our growing product portfolios after receiving the license from DRDO. Our countries medical infrastructure is really struggling with the scarcity of oxygen capacities. We hope the availability of an effective treatment such as 2-DG will considerably ease the pressure and offer patients much-needed and timely therapy options. Most patients ailing from moderate to severe symptoms can benefit from its use."
We are on Telegram!
JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.
Click Here!
Follow Us On:
